DDX55 and cancer: Considering that NPC cells can also stimulate the secretion of cytokines, hence we speculated that differences in the expression of DDX55 in plasma from patients with differences in IC efficacy is related to the modulation of RNA binding and ATP-dependent helicase activity by small molecules, or disrupting certain protein-protein interactions implicated in cancer progression (43).